Abstract
Persons of blood group O are at increased risk of developing cholera gravis. In a randomized, placebo-controlled, double-blind safety-immunogenicity trial of live oral cholera vaccine CVD 103-HgR in 5- to 9-year-old Chilean children, vibriocidal antibody seroconversion (74% overall) did not differ by blood group. However, the reciprocal geometric mean titer (GMT) in blood group O vaccines (GMT = 486) was higher than that in non-O vaccines (GMT = 179) (P < 0.02).
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
ABO Blood-Group System*
-
Antibodies, Bacterial / immunology*
-
Blood Bactericidal Activity
-
Child
-
Chile
-
Cholera / immunology
-
Cholera / prevention & control*
-
Cholera Vaccines / immunology*
-
Cytotoxicity, Immunologic
-
Dose-Response Relationship, Immunologic
-
Double-Blind Method
-
Humans
-
Vaccines, Attenuated / immunology
-
Vibrio cholerae / immunology*
Substances
-
ABO Blood-Group System
-
Antibodies, Bacterial
-
Cholera Vaccines
-
Vaccines, Attenuated